180 related articles for article (PubMed ID: 36733161)
21. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
22. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
23. [Advances of optimized neoadjuvant therapy in the treatment of locally advanced rectal cancer].
Fan J; Zhu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):527-533. PubMed ID: 31238633
[TBL] [Abstract][Full Text] [Related]
24. Post-Operative Morbidity and Mortality Following Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Sutera P; Solomina J; Wegner RE; Abel S; Monga D; Finley G; McCormick J; Kirichenko AV
J Gastrointest Cancer; 2021 Sep; 52(3):976-982. PubMed ID: 32936391
[TBL] [Abstract][Full Text] [Related]
25. [Rectal cancer : Is the era for de-escalation arrived?].
Brouquet A
Rev Prat; 2022 Jan; 72(1):50-54. PubMed ID: 35258254
[TBL] [Abstract][Full Text] [Related]
26. [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].
Gu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):507-513. PubMed ID: 31238630
[TBL] [Abstract][Full Text] [Related]
27. Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer.
Kang MK
World J Gastroenterol; 2023 Feb; 29(6):1011-1025. PubMed ID: 36844136
[TBL] [Abstract][Full Text] [Related]
28. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Huang MY; Huang CW; Wang JY
Kaohsiung J Med Sci; 2020 Mar; 36(3):152-159. PubMed ID: 31814296
[TBL] [Abstract][Full Text] [Related]
29. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Voogt ELK; Schaap DP; van den Berg K; Nieuwenhuijzen GAP; Bloemen JG; Creemers GJ; Willems J; Cnossen JS; Peulen HMU; Nederend J; van Lijnschoten G; Burger JWA; Rutten HJT
Eur J Surg Oncol; 2021 Sep; 47(9):2429-2435. PubMed ID: 34030921
[TBL] [Abstract][Full Text] [Related]
30. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis.
Xiong K; Bao T; Cao Y; Hu W; Deng J; Chen J; Xiao T
Int J Colorectal Dis; 2023 Apr; 38(1):89. PubMed ID: 37004572
[TBL] [Abstract][Full Text] [Related]
32. [Transition of treatment strategy for locally advanced rectal cancer towards "watch and wait"].
Xiao WW; Chen G
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):514-520. PubMed ID: 31238631
[TBL] [Abstract][Full Text] [Related]
33. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
Jin J; Tang Y; Hu C; Jiang LM; Jiang J; Li N; Liu WY; Chen SL; Li S; Lu NN; Cai Y; Li YH; Zhu Y; Cheng GH; Zhang HY; Wang X; Zhu SY; Wang J; Li GF; Yang JL; Zhang K; Chi Y; Yang L; Zhou HT; Zhou AP; Zou SM; Fang H; Wang SL; Zhang HZ; Wang XS; Wei LC; Wang WL; Liu SX; Gao YH; Li YX
J Clin Oncol; 2022 May; 40(15):1681-1692. PubMed ID: 35263150
[TBL] [Abstract][Full Text] [Related]
34. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
35. Oncological Outcomes and Hospital Costs of the Treatment in Patients With Rectal Cancer: Watch-and-Wait Policy and Standard Surgical Treatment.
Hupkens BJP; Breukink SO; Stoot JHMB; Toebes RE; van der Sande ME; Melenhorst J; Beets GL; Dirksen CD
Dis Colon Rectum; 2020 May; 63(5):598-605. PubMed ID: 32032202
[TBL] [Abstract][Full Text] [Related]
36. [Two Cases of Locally Advanced Lower Rectal Cancer with Pathological Complete Response after Cetuximab plus SOX as Neoadjuvant Chemotherapy].
Tokuhara K; Satake R; Ueyama Y; Yamamichi K; Sekimoto M
Gan To Kagaku Ryoho; 2021 Nov; 48(11):1405-1407. PubMed ID: 34795136
[TBL] [Abstract][Full Text] [Related]
37. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
38. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
39. [Preoperative Therapy for Advanced Lower Rectal Cancer in Our Department].
Ohno Y; Mazaki J; Ishizaki T; Enomoto M; Wada T; Watanabe M; Kasahara K; Yamada E; Takano Y; Nagakawa Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2245-2247. PubMed ID: 33468922
[TBL] [Abstract][Full Text] [Related]
40. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer.
Zhang S; Zhang R; Li RZ; Wang QX; Chang H; Ding PR; Li LR; Wu XJ; Chen G; Zeng ZF; Xiao WW; Gao YH
Cancer Sci; 2021 Sep; 112(9):3607-3615. PubMed ID: 34146368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
